Fig. 6
From: High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing
Association of the rs13215402-associated gene RGS17 with cell growth and clinical features for prostate cancer. a, b Knockdown of RGS17 by siRNA significantly reduces prostate cancer cell proliferation in 22RV1 and LNCaP cells, measured by XTT colorimetric assay (absorbance at 450 nm, OD450); mean ± s.d. of three independent measurements. **P < 0.01, ***P < 0.001, ****P < 0.0001, two-tailed Student’s t-test. c Expression of RGS17 is higher in prostate adenocarcinoma than in normal prostate gland in TCGA data. d The RGS17 mRNA expression in patients with T3 stage are higher than T2/T1 stage in TCGA prostate cancer data. In c–d, RGS17 expression intensity is shown as log2 transformed expression value (read per million or RPM by RNA-seq). The upper, middle, and lower bounds of boxes represent the 75th, 50th, and 25th percentile of the values, respectively. The whiskers represent 95th to 5th percentile. Mann–Whitney U-tests (c) or Kruskal–Wallis test (d) were used to evaluate the statistical significance. e, f The patients with higher mRNA level of RGS17 have worse recurrence-free survival rate based on TCGA and Glinsky prostate cancer data52
